When a new drug application (NDA) or biologics license application (BLA) is deemed incomplete by the FDA, the agency can decide not to review the application by responding to a sponsor with a refuse to file letter. A refuse to file letter allows the FDA to inform a sponsor as quickly as possible of deficiencies in an NDA or BLA, helping companies to correct such issues rather than wait for FDA to issue a complete response letter (CRL).

<< Back to Glossary Index